We’ve long viewed 24 hours from sample to answer as a milestone that will encourage the last remaining Solid Organ Typing labs that have a rapid turnaround time for non-cadaveric samples to switch to routinely typing all non-cadaveric samples at high resolution by NGS.
BUDAPEST, Hungary and CAMBRIDGE, Mass. (PRWEB) February 03, 2020
Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce that OmniType, the 11-locus, single tube multiplex successor to Holotype HLA is available through an Early Access Program (EAP) from today. OmniType is a best-in-class product featuring locus-multiplexing and short library preparation, for HLA genotyping from sample to answer in less than 24 hours.
“OmniType paves the way for a better laboratory workflow, reducing time and costs associated with the HLA testing.” Efi Melista, Head of Product. “Access for early adopters will be through the worldwide EAP with the first evaluators already receiving their kits in January for immediate testing”. The requirements for OmniType were driven by collating customer feedback, and during the vendor collaborations to find the best technology.
Omixon has been recruiting labs to join the EAP since it was first announced at the American Society for Histocompatibility and Immunogenetics (ASHI) in Pittsburgh, PA, September 2019. Over a dozen labs have already signed up to participate in the EAP and only a limited number of opportunities to be involved remain. OmniType is available worldwide, to existing customers, and potential customers, appropriately resourced to evaluate the technology. The OmniType EAP is expected to last approximately six months, and the data collected by Omixon and by individual participating labs will be published at future ASHI or EFI Annual Meetings.
“We’ve long viewed 24 hours from sample to answer as a milestone that will encourage the last remaining Solid Organ Typing labs that have a rapid turnaround time for non-cadaveric samples to switch to routinely typing all non-cadaveric samples at high resolution by NGS” says Dr Peter Meintjes, CEO at Omixon. “This removes all doubt that a single NGS technology can afford labs the opportunity to abandon legacy technologies like SSP, SSO, SBT and even qPCR for all routine typings except those from deceased donors”.
Omixon expects OmniType to outperform current NGS-based HLA typing tests on all relevant metrics in clinical labs, i.e. speed, throughput, reliability and accuracy. Users can now benefit from the fastest LR-PCR amplification (2 hours, 15 minutes) of all 11 HLA loci in a single tube and a rapid and simple library preparation workflow that enables DNA samples to be ready for sequencing in about 6 hours.
“Our number one priority for developing a multiplexed clinical diagnostic has been the genotyping accuracy, but importantly the market has also driven us to improve the speed and reliability. We are delighted by the quality of OmniType” says Dr. Gergely Tolgyesi, Technical Lead of Assay R&D.
OmniType is the start of Omixon’s innovative molecular diagnostics pipeline with more announcements expected throughout 2020 on new product launches and future EAPs.
Labs interested in participation in the Early Access Program for OmniType may email firstname.lastname@example.org for more information and acceptance into the program.
Contacts at Omixon
Peter Meintjes, PhD
Chief Executive Officer
+1 203 947 2772
Nora Nagy, MBA
Head of Market Development and Marketing
+36 30 633 3050
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 50 hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit omixon.com